|
CN111808098A
|
|
Quinoline derivatives, pharmaceutically acceptable salts thereof, and methods of use thereof
|
|
WO2020150306A1
|
|
Substituted fused imidazole derivatives and methods of treating sickle cell disease and related complications
|
|
WO2020117886A1
|
|
Methods of inhibiting osteoclastogenesis and osteoclast activity
|
|
WO2020086388A1
|
|
Glucokinase activator compositions for the treatment of cognitive impairment
|
|
CA3110582A1
|
|
Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
|
|
AU2019287437A1
|
|
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
|
|
EP3790549A1
|
|
Therapeutic uses of glp1r agonists
|
|
WO2019190822A1
|
|
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
WO2019190823A1
|
|
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
WO2018009539A1
|
|
Inhibitors of hexokinase and methods of use thereof
|
|
CN108779099A
|
|
Piperidine derivative and its application method
|
|
WO2016196890A1
|
|
Inhibitors of hexokinase and methods of use thereof
|
|
WO2016089648A1
|
|
Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
|
|
EP3756661A1
|
|
Use of a ppar-delta agonist for treating muscle atrophy
|
|
CN112263552A
|
|
Solid compositions comprising glucokinase activators and methods of making and using same
|
|
SG11201504778UA
|
|
Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
|
|
US2014100218A1
|
|
Treatment of mild and moderate Alzheimer's disease
|
|
NZ705813A
|
|
Treatment of mild and moderate alzheimer’s disease
|
|
MX2014013105A
|
|
Glucokinase activator compositions for the treatment of diabetes.
|
|
NZ724595A
|
|
Glucokinase activator compositions for the treatment of diabetes
|
